AZN Stock Analysis: AstraZeneca | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 289.138m USD | 12M Return: 7.7% | GB0009895292 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 556M
EPS Trend: 86.5%
Qual. Beats: 2
Rev. Trend: 98.4%
Warnings
Tailwinds
Seasonality 11.8 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
AstraZeneca PLC is a UK-headquartered biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across six main therapeutic areas: oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its product portfolio spans well-established drugs such as Crestor, Nexium, and Symbicort alongside newer oncology and rare disease treatments like Tagrisso, Enhertu, Ultomiris, and Wainua. The company sells to primary and specialty care physicians through distributors and local representative offices across the UK, the Americas, Europe, Asia, Africa, and Australasia.
The company has been expanding its research capabilities through strategic partnerships, including agreements with Tempus and Pathos to build a multimodal AI foundation model for oncology, with CSPC Pharmaceutical Group to develop oral drug candidates, and with Nucs AI to apply artificial intelligence to predict responses to therapeutic radioconjugates. These collaborations reflect the broader pharmaceutical industry shift toward AI-enabled drug discovery and external innovation partnerships to supplement in-house R&D pipelines.
AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, UK. It was originally known as Zeneca Group PLC and adopted its current name in April 1999 following the merger of Swedens Astra AB and the UKs Zeneca Group. As a large-cap pharmaceutical company, its revenue is largely dependent on prescription drug sales subject to regulatory approval, patent protection timelines, and reimbursement decisions across multiple national health systems.
- Tagrisso and Imfinzi drive oncology segment revenue growth
- Farxiga expansion in chronic kidney disease lifts cardiovascular portfolio
- China market pricing pressure weighs on emerging market revenue
- Datroway and Enhertu launch progress shapes oncology pipeline outlook
- Lynparza PARP inhibitor competition from GSK and Pfizer pressures share
| Net Income: 11.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 0.29% < 20% (prev -7.08%; Δ 7.37% < -1%) |
| CFO/TA 0.11 > 3% & CFO 13.3b > Net Income 11.0b |
| Net Debt (28.8b) to EBITDA (21.4b): 1.35 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago -0.06% < -2% |
| Gross Margin: 80.09% > 18% (prev 82.38%; Δ -2.30% > 0.5%) |
| Asset Turnover: 53.10% > 50% (prev 50.79%; Δ 2.31% > 0%) |
| Interest Coverage Ratio: 8.45 > 6 (EBIT TTM 15.0b / Interest Expense TTM 1.77b) |
| A: 0.00 (Total Current Assets 31.4b - Total Current Liabilities 31.2b) / Total Assets 120b |
| B: 0.12 (Retained Earnings 14.0b / Total Assets 120b) |
| C: 0.13 (EBIT TTM 15.0b / Avg Total Assets 117b) |
| D: 0.76 (Book Value of Equity 51.6b / Total Liabilities 68.0b) |
| Altman-Z'' = 2.05 = BBB |
| DSRI: 1.07 (Receivables 16.4b/14.3b, Revenue 62.2b/58.1b) |
| GMI: 1.03 (GM 82.38% / 80.09%) |
| AQI: 0.97 (AQ_t 0.60 / AQ_t-1 0.62) |
| SGI: 1.07 (Revenue 62.2b / 58.1b) |
| TATA: -0.02 (NI 11.0b - CFO 13.3b) / TA 120b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of November 12, 2026, the stock is trading at USD 185.48 with a total of 1,433,374 shares traded. Over the past week, the price has changed by -1.87%, over one month by +17.15%, over three months by +16.84% and over the past year by +7.69%.
Current recommended Stop Loss: 178.40 (which is 3.8% or 1.5 ATR below the current price).
AstraZeneca has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy AZN.
- StrongBuy: 7
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 207.7 | 12% |
P/E Trailing = 26.3692
P/E Forward = 16.4745
P/S = 4.6348
P/B = 5.6022
P/EG = 1.3494
Revenue TTM = 62.2b USD
EBIT TTM = 15.0b USD
EBITDA TTM = 21.4b USD
Long Term Debt = 26.5b USD (from longTermDebt, last quarter)
Short Term Debt = 5.38b USD (from shortTermDebt, last quarter)
Debt = 36.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.78b
Net Debt = 28.8b USD (calculated: Debt 36.9b - CCE 8.15b)
Enterprise Value = 318b USD (289b + Debt 36.9b - CCE 8.15b)
Interest Coverage Ratio = 8.45 (Ebit TTM 15.0b / Interest Expense TTM 1.77b)
EV/FCF = 34.10x (Enterprise Value 318b / FCF TTM 9.32b)
FCF Yield = 2.93% (FCF TTM 9.32b / Enterprise Value 318b)
FCF Margin = 14.99% (FCF TTM 9.32b / Revenue TTM 62.2b)
Net Margin = 17.68% (Net Income TTM 11.0b / Revenue TTM 62.2b)
Gross Margin = 80.09% ((Revenue TTM 62.2b - Cost of Revenue TTM 12.4b) / Revenue TTM)
Gross Margin QoQ = 74.61% (prev 83.60%)
Tobins Q-Ratio = 2.66 (Enterprise Value 318b / Total Assets 120b)
Interest Expense / Debt = 4.80% (Interest Expense 1.77b / Debt 36.9b)
Taxrate = 17.02% (2.25b / 13.2b)
NOPAT = 12.4b (EBIT 15.0b * (1 - 17.02%))
Current Ratio = 1.01 (Total Current Assets 31.4b / Total Current Liabilities 31.2b)
Debt / Equity = 0.71 (Debt 36.9b / totalStockholderEquity, last quarter 51.6b)
Debt / EBITDA = 1.35 (Net Debt 28.8b / EBITDA 21.4b)
Debt / FCF = 3.08 (Net Debt 28.8b / FCF TTM 9.32b)
Total Stockholder Equity = 49.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.39% (Net Income 11.0b / Total Assets 120b)
RoE = 22.21% (Net Income TTM 11.0b / Total Stockholder Equity 49.5b)
RoCE = 19.71% (EBIT 15.0b / Capital Employed (Equity 49.5b + L.T.Debt 26.5b))
RoIC = 13.68% (NOPAT 12.4b / Invested Capital 90.8b)
WACC = 6.00% (E(289b)/V(326b) * Re(6.26%) + D(36.9b)/V(326b) * Rd(4.80%) * (1-Tc(0.17)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.00 | Cagr: 0.0%
[DCF] Terminal Value 75.09% ; FCFF base≈9.42b ; Y1≈9.26b ; Y5≈9.39b
[DCF] Fair Price = 76.06 (EV 147b - Net Debt 28.8b = Equity 118b / Shares 1.55b; r=8.35% [WACC [floored]]; 5y FCF grow -2.56% → 2.50% )
EPS Correlation: 86.55 | EPS CAGR: 27.19% | SUE: 2.46 | # QB: 2
Revenue Correlation: 98.44 | Revenue CAGR: 11.87% | SUE: N/A | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=10.12 | Chg30d=+0.35% | Revisions=+0% | GrowthEPS=+121.0% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=11.32 | Chg30d=-2.27% | Revisions=+0% | GrowthEPS=+11.8% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +0% (up=2, down=2)